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BACKGROUND
Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most crypto-
genic strokes are considered to be embolic and of undetermined source. An ear-
lier randomized trial showed that rivaroxaban is no more effective than aspirin in 
preventing recurrent stroke after a presumed embolic stroke from an undeter-
mined source. Whether dabigatran would be effective in preventing recurrent 
strokes after this type of stroke was unclear.
METHODS
We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose 
of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once 
daily in patients who had had an embolic stroke of undetermined source. The 
primary outcome was recurrent stroke. The primary safety outcome was major 
bleeding.
RESULTS
A total of 5390 patients were enrolled at 564 sites and were randomly assigned to 
receive dabigatran (2695 patients) or aspirin (2695 patients). During a median 
follow-up of 19 months, recurrent strokes occurred in 177 patients (6.6%) in the 
dabigatran group (4.1% per year) and in 207 patients (7.7%) in the aspirin group 
(4.8% per year) (hazard ratio, 0.85; 95% confidence interval [CI], 0.69 to 1.03; 
P = 0.10). Ischemic strokes occurred in 172 patients (4.0% per year) and 203 pa-
tients (4.7% per year), respectively (hazard ratio, 0.84; 95% CI, 0.68 to 1.03). Major 
bleeding occurred in 77 patients (1.7% per year) in the dabigatran group and in 
64 patients (1.4% per year) in the aspirin group (hazard ratio, 1.19; 95% CI, 0.85 
to 1.66). Clinically relevant nonmajor bleeding occurred in 70 patients (1.6% per 
year) and 41 patients (0.9% per year), respectively.
CONCLUSIONS
In patients with a recent history of embolic stroke of undetermined source, dabi-
gatran was not superior to aspirin in preventing recurrent stroke. The incidence of 
major bleeding was not greater in the dabigatran group than in the aspirin group, 
but there were more clinically relevant nonmajor bleeding events in the dabigatran 
group. (Funded by Boehringer Ingelheim; RE-SPECT ESUS ClinicalTrials.gov number, 
NCT02239120.)
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Ischemic infarctions account for the majority of strokes and are classified by their cause: large-artery extracranial or intracra-
nial atherosclerosis, embolism from a cardiac 
source, small-artery occlusion, and other, less 
common causes.1 However, 20 to 30% of ische-
mic strokes are categorized as cryptogenic,2,3 
and a proportion of these are further classified 
as embolic strokes of undetermined source if a 
pattern of infarction that suggests an embolic 
(nonlacunar) cause is present on brain imaging 
but no source for the embolus is identified after 
a series of tests is performed to try to find the 
source.4,5
Guidelines for secondary prevention of stroke 
in patients who have had a cryptogenic stroke 
recommend administration of antiplatelet agents, 
and treatment may include aspirin, a combina-
tion of extended-release dipyridamole and aspi-
rin, or clopidogrel and aspirin.6 Oral anticoagu-
lants, including dabigatran etexilate, have an 
established role in reducing the incidence of re-
current strokes among patients with high-risk car-
dioembolic factors, such as atrial fibrillation.7,8
We conducted the RE-SPECT ESUS trial (Ran-
domized, Double-Blind, Evaluation in Secondary 
Stroke Prevention Comparing the Efficacy and 
Safety of the Oral Thrombin Inhibitor Dabigat-
ran Etexilate versus Acetylsalicylic Acid in Pa-
tients with Embolic Stroke of Undetermined 
Source) to compare the efficacy and safety of 
dabigatran with those of aspirin for the preven-
tion of recurrent stroke.
Me thods
Study Design and Oversight
RE-SPECT ESUS was an international, double-
blind, parallel-group, randomized trial. Patients 
were enrolled during the period from December 
2014 through January 2018 at 564 sites in 42 
countries. The trial was approved by the ethics 
committee at each participating site. The study 
rationale, design, and methods have been pub-
lished previously,9 and the protocol, including the 
statistical plan, is available with the full text of 
this article at NEJM.org.
The executive committee and representatives 
of the sponsor, Boehringer Ingelheim, developed 
the protocol and were responsible for supervis-
ing the trial and making protocol amendments. 
An independent data monitoring committee 
assessed safety outcomes and study conduct. An 
independent adjudication committee, whose mem-
bers were unaware of the treatment assign-
ments, reviewed and classified primary and 
secondary efficacy outcomes and major bleeding 
events.
The sponsor provided the investigational drugs, 
collected the data, performed the statistical 
analysis, and paid for professional editing of an 
earlier version of the manuscript for submission. 
Confidentiality agreements were in place be-
tween the investigators and authors and the 
sponsor. The executive committee drafted the 
manuscript. All the authors vouch for the accu-
racy and completeness of the data and reporting 
of adverse events and for the fidelity of the trial 
to the protocol. All patients provided written in-
formed consent before participating in the trial.
Trial Population
Patients 60 years of age or older were eligible for 
enrollment if they had had an embolic stroke 
of undetermined source within the previous 
3 months or, if they had at least one vascular 
risk factor, within the previous 6 months; pa-
tients 18 to 59 years of age were eligible if they 
had had a qualifying stroke within the previous 
3 months and had at least one additional vascu-
lar risk factor.9 Exclusion criteria are provided in 
Table S1 in the Supplementary Appendix, avail-
able at NEJM.org.
Embolic stroke of undetermined source was 
defined4 as a nonlacunar ischemic stroke (de-
tected by brain imaging) in a patient in whom 
no extracranial or intracranial atherosclerosis 
causing 50% or greater stenosis in arteries sup-
plying the area of the stroke was detected by 
arterial imaging or cervical and transcranial 
Doppler ultrasonography, no atrial fibrillation 
lasting longer than 6 minutes10 was shown by 
cardiac rhythm monitoring for 20 hours or lon-
ger, no intracardiac thrombus was detected by 
transthoracic or transesophageal echocardiogra-
phy, and no other specific cause of stroke was 
identified.
Trial Treatments
Patients were randomly assigned in a 1:1 ratio, 
in a double-blind manner, to receive dabigatran 
and aspirin placebo or aspirin and dabigatran 
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placebo (Fig. S1 in the Supplementary Appen-
dix). Dabigatran was administered at a dose of 
150 mg twice daily, but in patients 75 years of 
age or older and in patients who had an esti-
mated creatinine clearance of 30 to 50 ml per 
minute, dabigatran was administered at a dose 
of 110 mg twice daily. Patients in the aspirin 
group were given aspirin in nonenteric-coated 
form at a dose of 100 mg once daily. Patients 
with coronary heart disease who were assigned 
to the dabigatran group could receive aspirin for 
treatment of their coronary heart disease; patients 
in the aspirin group who had coronary heart dis-
ease received aspirin plus placebo. The trial treat-
ment period was planned to be a minimum of 
6 months and a maximum of 3.5 years.
Outcomes
The primary efficacy outcome was recurrent stroke 
of ischemic, hemorrhagic, or unspecified type, 
assessed in a time-to-event analysis. The two 
key secondary efficacy outcomes were ischemic 
stroke and a composite of nonfatal stroke, non-
fatal myocardial infarction, or death from cardio-
vascular causes, with both outcomes evaluated 
in time-to-event analyses. Other secondary effi-
cacy outcomes were disabling recurrent stroke 
and death from any cause. Disabling recurrent 
stroke was defined by a score on the modified 
Rankin scale of 4 or more 3 months after a re-
current stroke; scores on the modified Rankin 
scale range from 0 to 6, with 0 indicating no 
deficit and 6 indicating death. Tertiary efficacy 
outcomes are shown in Table S2 in the Supple-
mentary Appendix. The primary safety outcome 
was major bleeding according to International 
Society on Thrombosis and Hemostasis (ISTH) 
criteria, assessed in a time-to-event analysis.11 
Additional safety outcomes were nonmajor bleed-
ing resulting in hospitalization, medical or sur-
gical intervention, or change, interruption, or 
discontinuation of the trial drug (i.e., clinically 
relevant nonmajor bleeding) and a composite of 
major bleeding or clinically relevant nonmajor 
bleeding.
Statistical Analysis
We calculated that the trial would have 92% 
power to detect a 30% lower risk of recurrent 
stroke (the primary outcome) in the dabigatran 
group than in the aspirin group. The targeted 
number of recurrent strokes confirmed by the 
independent adjudication committee in this event-
driven trial was 353 strokes. The original plan 
was to randomly assign 6000 patients over the 
course of 2.5 years, with a planned maximum 
observation period of 3 years. Because recruit-
ment was slower than planned and the primary 
event rate was higher than expected, the recruit-
ment period was extended to 3 years, which re-
sulted in a total observation period of 3.5 years, 
and the target total sample size was reduced to 
5390 patients.
All analyses were performed in the intention-
to-treat population unless otherwise specified; 
analysis of data from patients who were lost to 
follow-up was based on the last day their status 
was known. A Cox proportional-hazards regres-
sion model, adjusted for the covariates of age, 
renal impairment (baseline creatinine clearance 
<50 or ≥50 ml per minute), and transient ische-
mic attack or stroke before the index stroke, was 
the prespecified model for the analysis of out-
comes. However, the assumption of proportional 
hazards was not satisfied for the primary out-
come; therefore, we explored whether the treat-
ment effect varied according to time (after inspec-
tion of the Kaplan–Meier curves), with additional 
analyses describing the results separately before 
and after 1 year in a piecewise Cox model.
To control for type I errors, a hierarchical 
analysis plan stipulated that if the results for the 
primary outcome were not statistically signifi-
cant, key secondary outcomes would be reported 
without claims of statistical significance. No 
multiplicity adjustments were planned for other 
secondary outcomes, and all confidence inter-
vals reported for secondary outcomes were un-
adjusted for multiple comparisons. On-treatment 
analyses were performed as sensitivity analyses. 
No imputation of missing data was performed. 
Tests for the interaction of treatment with vari-
ous subgroups were performed to evaluate the 
consistency of results with respect to the primary 
outcome and major bleeding. A total of 22 sub-
groups were prespecified for analysis. Results 
for 11 prespecified subgroups of greatest clinical 
interest are presented; 1 subgroup (assignment 
to dabigatran dose of 110 mg vs. 150 mg) was 
analyzed post hoc.
R esult s
Participants and Follow-up
A total of 5830 patients were screened, and 5390 
were randomly assigned to a treatment group 
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(2695 in each group) (Fig. 1). Patients were re-
cruited from Europe (58.8%), Asia (22.2%), North 
America (11.0%), and Latin America (4.2%). The 
mean age of the patients was 64.2 years, and 
36.9% were women. Patients in the two groups 
had similar baseline clinical and demographic 
characteristics, except for age; patients in the 
dabigatran group were a mean of 0.6 years older 
than those in the aspirin group (Table 1). Patent 
foramen ovale was diagnosed in 680 patients 
(12.6%), with similar numbers in the two treat-
ment groups.
The median time from the qualifying first 
stroke to randomization was 44 days (interquar-
tile range, 21 to 80). At the time of randomiza-
tion, the median score on the National Institutes 
of Health Stroke Scale (NIHSS; scores range 
from 0 to 42, with higher scores indicating more 
neurologic deficits) resulting from the qualify-
ing stroke was 1 (interquartile range, 0 to 2). In 
addition to the minimum required 20 hours of 
electrocardiogram (ECG) monitoring, extended 
ECG monitoring with an outpatient monitoring 
device was performed in 14% of the patients, 
and 6% of the patients received an implantable 
loop recorder to monitor cardiac rhythm. A total 
of 24 patients in the dabigatran group (0.9%) 
and 20 in the aspirin group (0.7%) were found 
Figure 1. Enrollment, Randomization, and Treatment.
Patients who did not receive the trial medication and those who discontinued the study early were still followed, and 
vital status was known for nearly all the patients (99.4%) at the end of the trial; data for 33 patients (0.6%) were 
censored because their vital status could not be verified at the end of the trial.
5390 Underwent randomization
5830 Patients were assessed for eligibility
440 Were excluded
268 Did not meet inclusion criteria
108 Declined to participate
64 Had other reason
2695 Were assigned to receive dabigatran
2084 Were assigned to 150 mg, twice daily
611 Were assigned to 110 mg, twice daily
2695 Were assigned to receive aspirin
19 Were lost to follow-up 14 Were lost to follow-up
1886 Did not discontinue dabigatran
790 Discontinued dabigatran
555 Had adverse event
142 Withdrew
93 Had other reason
1954 Did not discontinue aspirin
720 Discontinued aspirin
499 Had adverse event
127 Withdrew
94 Had other reason
2676 Had vital status known
2620 Completed follow-up
56 Died
2681 Had vital status known
2623 Completed follow-up
58 Died
2676 Received at least one dose of dabigatran
19 Did not receive a dose of dabigatran
2674 Received at least one dose of aspirin
21 Did not receive a dose of aspirin
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Characteristic
Dabigatran Group  
(N = 2695)
Aspirin Group  
(N = 2695)
Mean age — yr 64.5±11.4 63.9±11.4
Female sex — no. (%) 1001 (37.1)  986 (36.6)
Region — no. (%)
North America  300 (11.1)  294 (10.9)
Central Europe  369 (13.7)  335 (12.4)
Western Europe 1210 (44.9) 1254 (46.5)
Latin America  107 (4.0) 118 (4.4)
Asia  616 (22.9)  582 (21.6)
Other  93 (3.5) 112 (4.2)
Race — no. (%)†
White 1926 (71.5) 1966 (72.9)
Black  54 (2.0)  40 (1.5)
Asian  631 (23.4)  597 (22.2)
Other or missing  84 (3.1)  92 (3.4)
Mean body-mass index‡ 27.2±5.0 27.3±5.0
Current smoker — no. (%)  458 (17.0) 433 (16.1)
Creatinine clearance <50 ml per minute at baseline — no. (%) 227 (8.4) 203 (7.5)
Median time from index stroke to randomization (IQR) — days 46.0 (21.0–82.0) 43.0 (20.0–78.0)
Median score on modified Rankin Scale (IQR)§ 1 (0–2) 1 (0–2)
Median NIHSS score (IQR)¶ 1 (0–2) 1 (0–2)
Medical history — no. (%)
Previous TIA or stroke  475 (17.6)  500 (18.6)
Previous myocardial infarction 168 (6.2) 172 (6.4)
Coronary artery disease  301 (11.2)  276 (10.2)
Hypertension 1996 (74.1) 1985 (73.7)
Diabetes mellitus  585 (21.7)  639 (23.7)
Hyperlipidemia 1533 (56.9) 1510 (56.0)
Patent foramen ovale  319 (11.8)  361 (13.4)
Congestive heart failure‖ 117 (4.3) 124 (4.6)
LV dysfunction, ejection fraction ≤40%, or both  36 (1.3)  35 (1.3)
*  Plus–minus values are means ±SD. There were no significant differences between the groups except with respect to 
age (P = 0.03). P values were calculated with Student’s t-tests for continuous variables and chi-square tests for categori-
cal variables. Percentages may not total 100 because of rounding. IQR denotes interquartile range, LV left ventricular, 
and TIA transient ischemic attack.
†  Race was reported by the patient. Patients who identified as more than one race or did not identify their race were clas-
sified as other.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Scores on the modified Rankin scale range from 0 to 6, with higher scores indicating worse functional deficits.
¶  Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating 
worse neurologic deficits.
‖  No patients had New York Heart Association class IV heart failure.
Table 1. Characteristics of the Patients at Baseline.*
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after randomization to have atrial fibrillation 
(defined as cumulative duration of atrial fibrilla-
tion of more than 6 minutes during the extended 
monitoring period).
The median duration of follow-up was 19 
months (interquartile range, 13 to 27). Trial 
medication was discontinued in 671 patients in 
the dabigatran group (24.9%) and in 568 in the 
aspirin group (21.1%) before a primary outcome 
was reached. Adverse events were the main rea-
son for discontinuation in both groups; 555 pa-
tients in the dabigatran group and 499 patients 
in the aspirin group had adverse events leading 
to discontinuation (Fig. 1). The vital status of 19 
patients in the dabigatran group and 14 patients 
in the aspirin group could not be established.
Efficacy Outcomes
A recurrent stroke of any type (the primary out-
come) occurred in 177 patients (6.6%) in the 
dabigatran group (a rate of 4.1% per year) and in 
207 patients (7.7%) in the aspirin group (a rate of 
4.8% per year) (hazard ratio, 0.85; 95% confi-
dence interval [CI], 0.69 to 1.03; P = 0.10) (Table 2 
and Figs. 2A and 3). Results for secondary out-
comes are shown in Table 2. Ischemic strokes 
occurred in 172 patients (6.4%) in the dabigat-
ran group (a rate of 4.0% per year) and in 203 
patients (7.5%) in the aspirin group (a rate of 
4.7% per year) (hazard ratio, 0.84; 95% CI, 0.68 
to 1.03). A composite outcome event of nonfatal 
stroke, nonfatal myocardial infarction, or cardio-
vascular death occurred in 207 patients (7.7%) in 
Outcome
Dabigatran Group  
(N = 2695)
Aspirin Group  
(N = 2695)
Hazard Ratio  
(95% CI)†
no. of patients (annualized rate)
Primary outcome: first recurrent stroke 177 (4.1) 207 (4.8) 0.85 (0.69–1.03)‡
Key secondary outcomes§
Ischemic stroke 172 (4.0) 203 (4.7) 0.84 (0.68–1.03)
Composite of nonfatal stroke, nonfatal myocardial 
 infarction, or cardiovascular death
207 (4.8) 232 (5.4) 0.88 (0.73–1.06)
Other secondary outcomes
Disabling stroke 25 (0.6) 42 (0.9) 0.59 (0.36–0.96)
Death from any cause 56 (1.2) 58 (1.3) 0.96 (0.66–1.38)
Tertiary outcomes
Death from cardiovascular causes 19 (0.4) 24 (0.5) 0.78 (0.43–1.43)
Hemorrhagic stroke 6 (0.1) 7 (0.2) 0.86 (0.29–2.55)
TIA 43 (1.0) 37 (0.8) 1.14 (0.73–1.77)
Systemic embolism 6 (0.1) 11 (0.2) 0.54 (0.20–1.46)
Myocardial infarction 23 (0.5) 18 (0.4) 1.28 (0.69–2.38)
Venous thromboembolism 9 (0.2) 15 (0.3) 0.59 (0.26–1.34)
Net clinical outcome: disabling stroke, life-threatening 
bleeding, myocardial infarction, venous thrombo-
embolism, or death from cardiovascular causes
98 (2.2) 109 (2.5) 0.88 (0.67–1.16)
*  All outcomes were confirmed by an independent adjudication committee, except the score on the modified Rankin scale, 
which determines disabling stroke.
†  Hazard ratios have not been adjusted for multiple comparisons.
‡  P = 0.10 for the primary outcome of first recurrent stroke.
§  Because no adjustment for multiple comparisons was made for secondary outcomes and because the result of the pri-
mary outcome was not statistically significant, P values were not computed for secondary outcomes, and only confidence 
intervals unadjusted for multiplicity are shown.
Table 2. Efficacy Outcomes.*
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the dabigatran group (a rate of 4.8% per year) 
and in 232 patients (8.6%) in the aspirin group 
(a rate of 5.4% per year) (hazard ratio, 0.88; 95% 
CI, 0.73 to 1.06). Hemorrhagic strokes occurred 
in 6 patients (0.2%) in the dabigatran group (a rate 
of 0.1% per year) and in 7 patients (0.3%) in the 
Figure 2. Kaplan–Meier Curves for First Recurrent Stroke and First Major Bleeding Episode.
The inset in each panel shows the same data on an enlarged y axis.
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Figure 3. Analyses of Treatment Effects on Recurrent Stroke in Subgroups.
The trial may be underpowered to assess these subgroups. All subgroups were prespecified except dose assignment, which was post 
hoc. The CHA2DS2–VASc score reflects the risk of stroke among patients with atrial fibrillation. Scores range from 0 to 9, with higher 
scores indicating greater risk. TIA denotes transient ischemic attack.
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0.85 (0.62–1.19)
0.63 (0.43–0.94)
0.87 (0.68–1.11)
0.81 (0.56–1.17)
1.26 (0.68–2.33)
0.56 (0.30–1.06)
0.94 (0.70–1.26)
1.39 (0.51–3.75)
0.68 (0.44–1.03)
0.46 (0.14–1.51)
0.57 (0.39–0.83)
0.99 (0.78–1.26)
1.00 (0.77–1.29)
0.61 (0.44–0.86)
2.02 (0.76–5.38)
1.00 (0.72–1.38)
0.73 (0.53–1.00)
0.62 (0.37–1.04)
0.63 (0.37–1.07)
0.68 (0.48–0.95)
1.10 (0.83–1.46)
0.88 (0.71–1.08)
0.50 (0.24–1.07)
0.92 (0.72–1.18)
0.71 (0.50–1.01)
0.80 (0.64–1.00)
1.07 (0.67–1.71)
1.06 (0.69–1.65)
0.82 (0.56–1.18)
0.79 (0.59–1.06)
0.83 (0.68–1.03)
0.88 (0.45–1.71)
0.1
177/2695 (6.6)
11/285 (3.9)
57/961 (5.9)
66/901 (7.3)
43/548 (7.8)
123/1694 (7.3)
54/1001 (5.4)
24/300 (8.0)
16/369 (4.3)
87/1210 (7.2)
9/107 (8.4)
37/616 (6.0)
4/93 (4.3)
45/611 (7.4)
132/2084 (6.3)
113/1748 (6.5)
58/876 (6.6)
14/95 (14.7)
72/892 (8.1)
67/1219 (5.5)
24/489 (4.9)
23/226 (10.2)
59/1041 (5.7)
95/1424 (6.7)
165/2526 (6.5)
12/169 (7.1)
124/2220 (5.6)
53/475 (11.2)
139/2220 (6.3)
38/474 (8.0)
41/836 (4.9)
50/743 (6.7)
86/1116 (7.7)
160/2375 (6.7)
16/319 (5.0)
207/2695 (7.7)
10/320 (3.1)
58/965 (6.0)
79/928 (8.5)
60/482 (12.4)
144/1709 (8.4)
63/986 (6.4)
18/294 (6.1)
25/335 (7.5)
94/1254 (7.5)
7/118 (5.9)
54/582 (9.3)
9/112 (8.0)
71/546 (13.0)
136/2149 (6.3)
117/1797 (6.5)
87/827 (10.5)
6/97 (6.2)
75/937 (8.0)
89/1200 (7.4)
37/460 (8.0)
33/201 (16.4)
80/965 (8.3)
93/1525 (6.1)
191/2557 (7.5)
16/138 (11.6)
132/2195 (6.0)
75/500 (15.0)
174/2263 (7.7)
33/432 (7.6)
40/840 (4.8)
64/779 (8.2)
103/1076 (9.6)
188/2333 (8.1)
19/361 (5.3)
no. of events/total no. (%)
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aspirin group (a rate of 0.2% per year) (hazard 
ratio, 0.86; 95% CI, 0.29 to 2.55). Disabling strokes 
occurred in 25 patients (0.9%) in the dabigatran 
group (a rate of 0.6% per year) and in 42 patients 
(1.6%) in the aspirin group (a rate of 0.9% per 
year) (hazard ratio, 0.59; 95% CI, 0.36 to 0.96) 
(Fig. S2 in the Supplementary Appendix). Effi-
cacy outcomes during the on-treatment period 
for the treated population, which included all 
randomly assigned patients who received one or 
more doses of the assigned trial treatment, are 
shown in Table S3 in the Supplementary Appen-
dix. The results of a post hoc exploratory analy-
sis comparing the incidence of first recurrent 
strokes before 1 year and after 1 year are shown 
in Table S4 in the Supplementary Appendix.
The absence of a treatment effect on the pri-
mary outcome was consistent across most pre-
specified subgroups (Fig. 3). Patients with patent 
foramen ovale showed a treatment effect consis-
tent with the overall trial results; 16 of 319 pa-
tients (5.0%) with foramen ovale in the dabi-
gatran group and 19 of 361 patients (5.3%) with 
foramen ovale in the aspirin group had recurrent 
stroke (hazard ratio, 0.88; 95% CI, 0.45 to 1.71). 
Potential treatment interactions that were explor-
atory, and from which inferences cannot be made, 
were observed in two subgroups — those de-
fined according to the use of proton-pump in-
hibitors and according to the number of days 
from the index stroke to randomization (Fig. 3).
Safety Outcomes
Major bleeding occurred in 77 patients (2.9%) in 
the dabigatran group (a rate of 1.7% per year) 
and in 64 patients (2.4%) in the aspirin group 
(a rate of 1.4% per year) (hazard ratio, 1.19; 95% 
CI, 0.85 to 1.66) (Table 3 and Fig. 2B). The com-
posite outcome event of major or clinically rele-
vant nonmajor bleeding occurred more frequently 
with dabigatran than with aspirin (hazard ratio, 
1.44; 95% CI, 1.12 to 1.85) because of the excess 
of clinically relevant nonmajor bleeding episodes 
with dabigatran (hazard ratio, 1.73; 95% CI, 1.17 
to 2.54).
Intracranial hemorrhage occurred in 32 pa-
tients (1.2%) in both the dabigatran group and 
the aspirin group (a rate of 0.7% per year) (hazard 
ratio, 0.98; 95% CI, 0.60 to 1.60). The incidence 
of life-threatening bleeding did not differ be-
tween the two treatment groups (hazard ratio, 
0.83; 95% CI, 0.54 to 1.28) (Table 3). The treat-
ment effect on major bleeding was consistent 
across subgroups. Other safety outcomes are 
shown in Figure S3 and Tables S3, S5, and S6 in 
the Supplementary Appendix.
Discussion
The RE-SPECT ESUS trial showed no significant 
difference between the effect of dabigatran and 
that of aspirin on the risk of recurrent stroke 
among patients with embolic stroke of undeter-
Outcome
Dabigatran Group  
(N = 2695)
Aspirin Group  
(N = 2695)
Hazard Ratio 
(95% CI)†
no. of patients (annualized rate)
Major bleeding 77 (1.7) 64 (1.4) 1.19 (0.85–1.66)
Intracranial hemorrhage 32 (0.7) 32 (0.7) 0.98 (0.60–1.60)
Gastrointestinal bleeding 27 (0.6) 22 (0.5) 1.22 (0.70–2.15)
Life-threatening bleeding 38 (0.8) 45 (1.0) 0.83 (0.54–1.28)
Fatal bleeding and fatal hemorrhagic stroke‡ 1 (0.02) 6 (0.1) 0.17 (0.02–1.39)
Clinically relevant nonmajor bleeding 70 (1.6) 41 (0.9) 1.73 (1.17–2.54)
Major or clinically relevant nonmajor bleeding 145 (3.3) 101 (2.3) 1.44 (1.12–1.85)
*  All outcomes except clinically relevant nonmajor bleeding were confirmed by an independent adjudication committee.
†  Hazard ratios have not been adjusted for multiple comparisons.
‡  Three deaths were confirmed by the adjudication committee as fatal intracranial hemorrhage (all three in the aspirin group), 
and four deaths were confirmed by the adjudication committee as fatal hemorrhagic stroke (one in the dabigatran 
group and three in the aspirin group).
Table 3. Safety Outcomes.*
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mined source. The rate of recurrent stroke was 
4.1% per year among patients in the dabigatran 
group and 4.8% per year among patients in the 
aspirin group. Dabigatran was associated with 
major bleeding in 1.7% of the patients per year, 
and aspirin was associated with major bleeding 
in 1.4% of the patients per year. The percentages 
were similar in the two groups in all subcatego-
ries of major bleeding, but more patients in the 
dabigatran group than in the aspirin group had 
clinically relevant nonmajor bleeding.
Our hypothesis was that dabigatran would be 
more effective than aspirin for stroke prevention 
in patients with embolic stroke of undetermined 
source because many of these patients might 
have had an unrecognized source of cardiac 
embolism, including atrial fibrillation. Post hoc 
analysis suggested that dabigatran may have had 
an effect on stroke recurrence after 1 year, but no 
inferences can be made because of the post hoc 
nature of the analysis. A possible explanation for 
this temporal pattern might be a progressive in-
crease in the occurrence of asymptomatic, unde-
tected atrial fibrillation and other cardiac sources 
of embolism over time. The CRYSTAL-AF (Crypto-
genic Stroke and Underlying Atrial Fibrillation)12 
and FIND-AF (Finding Atrial Fibrillation in 
Stroke)13 trials in patients with cryptogenic stroke 
showed detection rates of atrial fibrillation of 
approximately 10 to 15% per year in populations 
that were similar to the RE-SPECT ESUS popula-
tion. In our trial, extended ECG monitoring after 
randomization was performed in only 14% of 
patients; therefore, we do not have a systematic 
assessment of the occurrence of atrial fibrilla-
tion. Whether patients with cryptogenic stroke 
who have atrial cardiopathy and are at a high risk 
for atrial fibrillation could benefit from antico-
agulation is being investigated in the ongoing 
ARCADIA trial (Atrial Cardiopathy and Antithrom-
botic Drugs In Prevention after Cryptogenic 
Stroke).14
Our trial design differed from that of 
 NAVIGATE ESUS (New Approach Rivaroxaban 
Inhibition of Factor Xa in a Global Trial versus 
ASA to Prevent Embolism in Embolic Stroke of 
Undetermined Source).15 NAVIGATE ESUS used a 
lower dose of rivaroxaban than has been used for 
stroke prophylaxis in patients with atrial fibril-
lation. In RE-SPECT ESUS, for patients 75 years 
of age or older or patients who had impaired 
renal function, we used the lower dose of dabi-
gatran (110 mg twice daily) according to slightly 
modified criteria from the European approved 
labeling for atrial fibrillation. The median follow-
up was 11 months in NAVIGATE ESUS as com-
pared with 19 months in RE-SPECT ESUS. The 
overall number of bleeding events in patients in 
the aspirin group was lower in NAVIGATE ESUS 
than in RE-SPECT ESUS. Aspirin was used in an 
enteric-coated form in NAVIGATE ESUS and in 
plain form in RE-SPECT ESUS.
The strengths of RE-SPECT ESUS are the 
large sample size and the broad distribution of 
international trial centers that may allow the 
results to be generalized. The stroke event rates 
matched the expectations that were used in the 
power calculation for the trial, and we reached 
the prespecified target number of recurrent 
strokes in this event-driven trial.
In conclusion, we found that dabigatran was 
not superior to aspirin in preventing recurrent 
stroke in patients who had had an embolic stroke 
of undetermined source. The incidence of major 
bleeding was not greater in the dabigatran group 
than in the aspirin group, but there were more 
clinically relevant nonmajor bleeding events in 
the dabigatran group.
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with the full text of this article at NEJM.org.
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